Sequencing Consumables Market Size & Growth Forecast 2026–2035, By Segments (Platform, Product, End-use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Sequencing Consumables Market size was worth USD 9.98 Billion in 2025 and is expected to grow at a 22.4% CAGR between 2026 and 2035, reaching USD 75.33 Billion by 2035. The industry revenue for 2026 is calculated at USD 12.01 billion.

• Base Year Value (2025): USD 9.98 Billion
• CAGR (2026-2035): 22.4%
• Forecast Year Value (2035): USD 75.33 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Key Takeaways

• North America region secured more than 41.2% revenue share in 2025, spurred by advanced genomics research infrastructure.
• Asia Pacific region will observe around 24% CAGR during the forecast period, driven by rising biotech and personalized medicine.
• Holding 66.64% share in 2025, the success of 2nd generation sequencing consumables segment was shaped by widespread adoption in research and diagnostics due to cost-effectiveness.
• The market share of reagents segment stood at 58.8% in 2025, propelled by essential role in sample preparation ensures high market demand.
• With a share of 46.35% in 2025, academic research institutes segment’s dominance was secured by extensive use in genomic research drives consumable demand.
• Key companies dominating the sequencing consumables market are Illumina (USA), Thermo Fisher Scientific (USA), QIAGEN (Germany), Roche (Switzerland), Oxford Nanopore (UK), Pacific Biosciences (USA), BGI Genomics (China), Agilent Technologies (USA), Bio-Rad (USA), Takara Bio (Japan).

Market Growth Drivers and Industry Trends

Rapid advancements in sequencing technologies increasing genomics research and clinical testing volumes

As sequencing platforms become faster, more automated, and capable of processing larger sample volumes at lower per-run cost, laboratories expand the scope and frequency of testing they can justify operationally. That shift directly supports the sequencing consumables market because every increase in instrument utilization translates into recurring purchases of library preparation kits, flow cells, reagents, and sample handling consumables. In practice, technology upgrades also move sequencing beyond specialized research settings into hospital laboratories, reference labs, and translational research programs, increasing testing throughput and reinforcing demand for standardized consumable workflows that fit validated, high-volume operations.

Expanding cancer diagnostics applications accelerating demand for high-throughput sequencing consumables

Cancer diagnostics is pushing sequencing into routine clinical decision-making, especially where broad genomic profiling is needed to identify mutations, guide targeted therapy selection, and monitor disease progression. This strengthens the sequencing consumables market by increasing the number of patient samples processed under time-sensitive and quality-controlled conditions, which favors repeat procurement of high-throughput reagent kits, target enrichment panels, and consumables designed for reliable batch processing. As oncology testing menus widen and laboratories build capacity for larger case loads, purchasing behavior shifts toward scalable consumable supply arrangements that can support continuous diagnostic throughput rather than occasional research use.

Growing adoption of personalized medicine driving recurring demand for sequencing reagent kits

Personalized medicine depends on molecular data to match therapies, assess patient risk, and refine treatment pathways, making sequencing an operational tool rather than an intermittent investigative method. That dynamic is increasing demand for the sequencing consumables market because reagent kits must be repurchased for each new patient cohort, follow-up analysis, or therapy-selection workflow, creating a recurring revenue base tied to clinical use rather than one-time capital investment. As providers and testing laboratories integrate genomics into care pathways, they prioritize consumables that offer reproducibility, compatibility with established platforms, and streamlined turnaround, increasing market penetration for standardized sequencing kits used in routine precision medicine programs.

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 55.24% share of the sequencing consumables market in 2025, bolstered by its dense installed base of sequencing platforms across research institutes, clinical laboratories, and biopharmaceutical settings. This leadership is reinforced by the region’s steady consumables pull-through, as routine sample processing, recurring reagent replacement, and high testing volumes translate directly into repeat purchasing activity. The market remains firmly anchored by the practical operating pattern of sequencing workflows, where established laboratories depend on consistent supplies of library preparation kits, flow cells, and related reagents to keep utilization rates high and turnaround times predictable.

Asia Pacific is projected to expand at a 24.64% CAGR over the forecast period, with growth in the sequencing consumables market being propelled by the rapid buildout of sequencing capacity across healthcare and research environments. As more laboratories adopt sequencing for broader diagnostic, academic, and applied use cases, consumables demand rises alongside instrument deployment because every additional run requires ongoing reagent and sample-preparation inputs. The region’s acceleration reflects this widening operational adoption curve, where expanding lab networks and rising workflow activity convert directly into recurring consumption rather than one-time capital spending.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Nascent
Cost-Sensitive Region	Low	Medium	Low	High	High
Regulatory Environment	Restrictive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Strong	Strong	Moderate	Weak
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	High	Medium	High	Low	Low
New Entrants / Startups	Dense	Moderate	Dense	Sparse	Sparse
Macro Indicators	Strong	Stable	Stable	Weak	Weak

No card data available for this language/report.

Segment Leadership and Growth Trends

  Platform Segment Analysis: 2nd Generation Sequencing Consumables (Largest Segment) vs 3rd Generation Sequencing Consumables (Fastest-Growing Segment)

Within the sequencing consumables market, 2nd Generation Sequencing Consumables held the strongest position in 2025 with a 64.86% share. This leadership is underpinned by the entrenched installed base of second-generation sequencing platforms across research and clinical laboratories, where routine workflows depend on well-established consumable purchasing cycles. Demand remains concentrated in this segment because laboratories prioritize compatibility, validated protocols, and consistent throughput for high-volume sequencing applications, which keeps 2nd Generation Sequencing Consumables at the center of recurring procurement activity.

3rd Generation Sequencing Consumables are emerging as the fastest-growing platform segment in the sequencing consumables market as end users increasingly adopt sequencing approaches that support more advanced read capabilities and evolving application needs. Growth is being backed by expanding use cases where laboratories require newer sequencing workflows that differ from conventional high-throughput routines, prompting fresh consumables demand tied to platform adoption. Relative to older alternatives, this segment gains momentum from its alignment with changing research requirements and the resulting shift in purchasing toward consumables designed for next-wave sequencing systems.

Product Segment Analysis: Kits (Largest Segment) vs Reagents (Fastest-Growing Segment)

Kits accounted for the largest position in the sequencing consumables market in 2025, capturing a 77.05% share. Their leadership reflects how laboratories often prefer complete, standardized consumable formats that simplify workflow execution and reduce variability across sequencing runs. In practice, kits remain the default purchasing choice because they package essential components into validated formats that support routine use, making them especially effective for labs focused on operational consistency, turnaround reliability, and easier protocol management.

Reagents represent the fastest-growing product segment in the sequencing consumables market, influenced by rising demand for more workflow flexibility as sequencing applications become broader and more specialized. Laboratories are increasingly seeking the ability to tailor consumable inputs around specific protocols, sample types, and platform requirements, which supports stronger momentum for standalone reagents relative to bundled alternatives. This shift is particularly relevant where users want tighter control over optimization and replenishment, making reagents a more responsive option as sequencing workflows diversify.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Platform	1st Generation Sequencing Consumables, 2nd Generation Sequencing Consumables, 3rd Generation Sequencing Consumables	2nd Generation Sequencing Consumables	3rd Generation Sequencing Consumables
Product	Kits, Reagents, Accessories	Kits	Reagents
End-use	Pharmaceutical and Biotechnology Companies, Hospitals and Laboratories, Academic Research Institutes, Others	Hospitals and Laboratories	Pharmaceutical and Biotechnology Companies
Application	Cancer Diagnostics, Infectious Disease Diagnostics, Reproductive Health Diagnostics, Pharmacogenomics, Agrigenomics, Others	Cancer Diagnostics	Pharmacogenomics

Competitive Landscape and Market Positioning

Top players in the sequencing consumables market:

1. Thermo Fisher Scientific Inc. (United States)

2. F. Hoffmann-La Roche Ltd. (Switzerland)

3. QIAGEN N.V. (Netherlands)

4. Agilent Technologies Inc. (United States)

5. Merck KGaA (Germany)

6. Takara Bio Inc. (Japan)

7. Oxford Nanopore Technologies plc (United Kingdom)

8. Beckman Coulter Inc. (United States)

9. BGI Genomics Co. Ltd. (China)

10. Illumina Inc. (United States)

The sequencing consumables market is benefiting from rising genomic research activity and increasing adoption of precision medicine technologies. Companies are expanding consumable portfolios with high-throughput reagents and workflow-optimized products that support faster and more accurate sequencing processes. Continuous investment in research and laboratory automation is also driving innovation across the sequencing consumables market.

Industry Development/News

Company Name	Date	Key Development
QIAGEN	Jul-25	QIAGEN launched its QIAseq xHYB Long Read Panels in the Netherlands to advance next-generation sequencing capabilities. The rollout directly addresses growing clinical and research demand for specialized sequencing consumables optimized for complex genomic regions.
Illumina, Inc.	Jan-25	Illumina, Inc. commercialized an update to its NovaSeq X Series, launching a single-flow-cell system alongside advanced operating software and new sequencing kits. The release scales workflow flexibility and updates high-throughput consumable options for global laboratory networks.
Illumina Inc.	Nov-23	Illumina Inc. introduced the Global Health Access Initiative in collaboration with the nonprofit FIND to expand access to sequencing tools. The program implements a tiered, reduced pricing structure for select sequencing consumables and addresses international supply chain constraints across low- and middle-income nations.
Thermo Fisher Scientific Inc.	May-23	Thermo Fisher Scientific and Pfizer established a strategic collaboration to expand local patient access to next-generation sequencing-based testing across more than 30 countries. The initiative enhances diagnostic capabilities for lung and breast cancer within historically underserved markets in Latin America, Africa, the Middle East, and Asia.